[ICD therapy in patients with coronary artery disease--incidence of adequate interventions].
The Implantable Cardioverter/Defibrillator (ICD) represents the therapy of choice for patients at risk of malignant ventricular arrhythmias. The survival benefit of the ICD vs antiarrhythmic therapy in patients with coronary artery disease and ventricular tachycardia has been proven. Recently, the ICD therapy has also been established for primary prevention in high risk patients. We report about the incidence of adequate ICD therapies in patients with coronary artery disease, who underwent ICD implantation at the University Hospital Zurich. 104 consecutive patients (97 men, 7 women, mean age of 67 +/- 10 years) with coronary artery disease, who underwent ICD implantation in accordance with the AHA/ACC/NASPE guidelines between January 2000 and July 2003 were included in the study. Follow-up was performed every three to six months, when all ICD therapies were documented. This documentation was used for analysis of adequate or inadequate ICD therapies. The mean follow-up time was 383 +/- 195 days. The time to the first adequate therapy was 201 +/- 283 days. The cumulative incidence for the first adequate therapy was 21% at six months, 39% at two years and 59% at four years. In 64% of patients, who experienced adequate ICD therapies, antitachycardia pacing (ATP) and in 36% an initial shock was delivered. ATP was successful in 83% of adequately delivered episodes. In the follow-up period 12 patients died. The benefit of the ICD was apparent in patients at risk for ventricular arrhythmias and coronary artery disease after a relatively short period of time, which underlines the important role of the ICD in primary and secondary prevention.